Keeping up with business and economy news from New Zealand
Provided by AGP
AGP Picks
View all
Perspectify News
Left-wing
Center-left
Neutral
Public Broadcaster
Gov't Institution
Center-right
Right-wing
Pro-Government
Gov't Propaganda
Indeterminate
Filter
5 hours ago
#opinion: The Truth About Cancer Drugs, Corporate Greed and Broken Political Promises
Left-wing
Waatea News
|
Owner: Manukau Urban Māori Authority & Te Whanau a Waipareira Charitable Trust (Non-profit)
As featured in:
@ Journalists!
Join
Press releases
Publish your press release
May. 9, 2026
Amplia Therapeutics and Australia New Zealand Gynaecological Oncology Group (Anzgog) Announce Ovarian Cancer Study
GlobeNewswire, Inc.
Melbourne, Australia, May 08, 2026 (GLOBE NEWSWIRE) -- HIGHLIGHTS Amplia and ANZGOG enter into agreement to conduct a clinical study in ovarian cancer evaluating narmafotinib in combination with standard-of-care chemotherapy Ovarian cancer...
May. 7, 2026
New Zealand Begins Talks with Australia, UK for Frigate Overhaul
MENAFN
(MENAFN) New Zealand has launched formal talks with Australia and the United Kingdom over replacing its ageing frigate fleet, as Wellington moves to shore up naval defenses before a critical capability gap emerges in the mid-2030s, Defense...
May. 7, 2026
New Zealand Eyes Japanese, UK Frigates
MENAFN
World and Middle East business and financial news, Stocks, Currencies, Market Data, Research, Weather and other data.
May. 6, 2026
New Zealand to Launch Citizenship Test in 2027
MENAFN
World and Middle East business and financial news, Stocks, Currencies, Market Data, Research, Weather and other data.
May. 8, 2026
Femasys Announces Financial Results for Quarter Ended March 31, 2026 and Provides Corporate Update
GlobeNewswire, Inc.
ATLANTA, May 08, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, announces its financial results...
May. 8, 2026
Artiva Biotherapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights
GlobeNewswire, Inc.
Initial AlloNK® (AB-101) clinical data demonstrated 71% ACR50 response in refractory rheumatoid arthritis (RA) patients with at least six months of follow-up in the company-sponsored Phase 2a basket trial, with no patients relapsing or requiring...
Video Stories
Discover Affinity Group Publishing
Sign up for:
New Zealand Business Daily
The daily local news briefing you can trust. Every day. Subscribe now.
Check Your Email!
We sent a one-time activation link to: .
Confirm it's you by clicking the email link.
If the email is not in your inbox, check spam or try again.
Welcome back!
is already signed up. Check your inbox for updates.
Explore More
